Aimmune Therapeutics, Inc. (AIMT) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET
Company Participants
DeDe Sheel - Vice President, Investor Relations
Jayson Dallas - President & Chief Executive Officer
Andrew Oxtoby - Chief Commercial Officer
Eric Bjerkholt - Chief Financial Officer
Daniel Adelman - Chief Medical Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Kennen MacKay - RBC Capital Markets
Brian Skorney - Baird
Zegbeh Jallah - Roth Capital Partners
Liisa Bayko - JMP Securities
Paul Choi - Goldman Sachs
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Aimmune First Quarter 2020 Earnings Call. [Operator Instructions] After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the call over to DeDe Sheel. Please proceed.
DeDe Sheel
Thank you, Zide [ph]. Good afternoon, and thank you for joining us today to discuss Aimmune's First Quarter 2020 financial results and recent operational highlights. Today's call will be webcast, which will be available on our corporate website at aimmune.com. Joining me on the call today are Dr. Jayson Dallas, President and Chief Executive Officer; Andrew Oxtoby, Chief Commercial Officer; and Eric Bjerkholt, Chief Financial Officer. After our prepared remarks, we will open the call for questions. Daniel Adelman, our Chief Medical Officer, will join us for the Q&A.
Before we begin, I would like to remind you that during today's call and Q&A session, we will be making forward-looking statements. These forward-looking statements include Aimmune's expectations regarding the potential effects of COVID-19 on our business and financial condition; the potential benefits of PALFORZIA; the commercial launch of PALFORZIA, including engagement of our commercial field team with allergists; the timing for when allergy practices may reopen; timing for initiating direct-to-consumer mobilization activities and timing for payers in the United States to add PALFORZIA to formularies; the
- Read more current AIMT analysis and news
- View all earnings call transcripts